Skip to main content

Table 4 Distribution of rs662799 polymorphism in the APOA5 gene in ESKD CVD + patients with different primary kidney disease

From: Apolipoprotein A5 gene polymorphism (rs662799) and cardiovascular disease in end-stage kidney disease patients

ESKD CVD + subgroup

Genotypes

MAF

OR (95% CI)a

P value

N

TT

TC

CC

 

for C alleleb

CGN

157

123 (78)

28 (18)

6 (4)

0.13

2.18 (1.33–3.58)

0.002

DN

146

102 (70)

34 (23)

10 (7)

0.18

3.40 (2.13–5.43)

 < 0.001

IN

64

51 (79.8)

11 (17)

2 (3.2)

0.12

1.99 (1.03–3.81)

0.037

PKD

41

32 (78)

7 (17.5)

2 (4.5)

0.13

2.32 (1.11–4.83)

0.023

Other

144

115 (79.5)

25 (17.5)

4 (3)

0.12

1.94 (1.16–3.24)

0.011

ESKD CVD-c

248

221 (89.1)

23 (9.3)

4 (1.6)

0.06

ref

-

  1. Genotype distribution is shown as numbers (%)
  2. ESKD End-stage kidney disease, CVD Cardiovascular disease, CGN Chronic glomerulonephritis, DN Diabetic nephropathy, IN Interstitial nephritis, PKD Polycystic kidney disease, APOA5 Apolipoprotein A5, MAF Minor allele frequency
  3. aOR was adjusted for age, sex, BMI, and hypertension
  4. bCalculated versus ESKD CVD- group
  5. cThe same ESKD patient population with different primary kidney diseases, but without CVD